GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (GMI), a privately held firm that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced it will present two posters that describe the activity of its lead drug candidate in animal models of diseases at the annual American Society of Hematology (ASH) meeting, December 7th-11th in Atlanta, GA.
